Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03573648 | Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer(ImmunoADAPT) | active not recruiting | Phase 2 | 33 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03716180 | DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC | active not recruiting | Phase 1 | 100 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 24, 2026 |
| clinicaltrials |
| NCT03927768 | Abbreviated Breast MRI (AB-MRI) With Golden-angle Radial Compressed-sensing and Parallel Imaging (GRASP) | active not recruiting | — | 264 | NYU Langone HealthOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04224272 | Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant | completed | Phase 2 | 51 | Jazz PharmaceuticalsINDUSTRY | 3 | Sep 24, 2026 | clinicaltrials |
| NCT04570956 | Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk | terminated | Phase 2 | 65 | Mayo ClinicOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04584255 | Niraparib + Dostarlimab In BRCA Mutated Breast Cancer | active not recruiting | Phase 2 | 66 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05384119 | Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer | terminated | Phase 1 | 6 | Tvardi Therapeutics, IncorporatedINDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05412225 | A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer | recruiting | Phase 1 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05444998 | Neoadjuvant Inetetamab and Pyrotinib and Nab-paclitaxel for HER2+Breast Cancer | completed | Phase 2 | 20 | Xijing HospitalOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05708235 | A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population(MiRaDoR) | active not recruiting | Phase 2 | 976 | MedSIROTHER | 2 | Sep 24, 2026 | clinicaltrials |
| NCT05898789 | Virtual Rehabilitation for Cancer Survivors | recruiting | N/A | 388 | University Health Network, TorontoOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05959291 | Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer(Free-HER) | active not recruiting | N/A | 20 | University of MiamiOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06018337 | A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) | active not recruiting | Phase 3 | 541 | DualityBio Inc.INDUSTRY | 17 | Sep 24, 2026 | clinicaltrials |
| NCT06179303 | Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer | recruiting | Phase 2 | 60 | University of WashingtonOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06251544 | TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer | recruiting | Phase 1 | 27 | Baylor College of MedicineOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06522568 | Testing a Mammography Decision Intervention in a Rural Setting | recruiting | N/A | 39 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07407920 | Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial | recruiting | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07408856 | CAN1012 in Pre-Malignant DCIS and LCIS | recruiting | Phase 1 | 24 | Providence Health & ServicesOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07595718 | AI-Based Phenome Data Analysis for Predicting the Onset of Major Diseases | recruiting | — | 1,000 | Jae Yong Jeon, MDOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07820228 | Survival Analysis of Early Triple Negative Breast Cancer (TNBC) Women Treated With Dose Dense Sequential Adjuvant Chemotherapy | completed | — | 3,648 | Hellenic Cooperative Oncology GroupOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07838649 | Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity | not yet recruiting | Phase 1 | 36 | Washington University School of MedicineOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03367676 | 12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)(SOBER) | terminated | Phase 2 | 78 | Ruijin HospitalOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03387553 | HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer | completed | Early Phase 1 | 31 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04040569 | A Phase I Dose Escalation Study of Single Fraction Pre-operative Partial Breast (S-PBI) for Early Stage Breast Cancer | active not recruiting | Phase 1 | 45 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04144907 | Protein Needs Study | recruiting | N/A | 40 | University of AlbertaOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04222413 | Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors | recruiting | Phase 1 | 116 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04400695 | A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 | recruiting | Phase 3 | 366 | RemeGen Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04715958 | SHAPE Neoadjuvant Chemotherapy Response | active not recruiting | Phase 2 / Phase 3 | 122 | Kibo NamOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04989504 | Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy | active not recruiting | Phase 3 | 216 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06253520 | Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | active not recruiting | Phase 1 | 210 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06534918 | Precise Oncology Interventions in Nutrition and Training (OnPoint)(OnPoint) | recruiting | N/A | 306 | University of MiamiOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06618287 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 416 | Bristol-Myers SquibbINDUSTRY | 10 | Sep 23, 2026 | clinicaltrials |
| NCT06633276 | Fast and Accurate Breast Cancer Diagnosis Using Nanopore Sequencing in Tanzania (Fast-ABCD Sequencing) | recruiting | — | 100 | University of BonnOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06999798 | An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast Cancer, The UTMOST2 Trial | recruiting | Phase 1 | 20 | Mayo ClinicOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07085767 | Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer(OPERA-02) | recruiting | Phase 3 | 1,000 | Olema Pharmaceuticals, Inc.INDUSTRY | 23 | Sep 23, 2026 | clinicaltrials |
| NCT07185568 | IntraOperative UltraSound Guided vs Wire Guided vs Magnetic Seed Guided Breast-Conserving Surgery for Non-palpable Tumors(MANOLA) | not yet recruiting | N/A | 1,302 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07214532 | Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer(SIGNAL-ER 101) | recruiting | N/A | 725 | Natera, Inc.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07339176 | Intratumoral N17350 in Advanced Solid Tumors(OP-NEU-101) | recruiting | Phase 1 / Phase 2 | 275 | Onchilles Pharma IncINDUSTRY | 2 | Sep 23, 2026 | clinicaltrials |
| NCT07401381 | A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer(SIE-1) | recruiting | Phase 1 | 120 | Rovi Pharmaceuticals LaboratoriesINDUSTRY | 3 | Sep 23, 2026 | clinicaltrials |
| NCT07502352 | Remotely-Delivered Cognitive Behavioral Stress Management for Breast Cancer (R-CBSM) | recruiting | N/A | 192 | University of MiamiOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07711847 | Personalized Prone Immobilization for Accelerated Partial Breast Radiotherapy(SHIELD) | recruiting | N/A | 30 | HeroSupport SAINDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07808086 | Role of Tumor Microbiota in the Response to Neoadjuvant Therapy in Patients Affected by Triple Negative Breast Cancer | recruiting | — | 30 | Istituti Clinici Scientifici Maugeri SpAOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07829848 | Response-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant Systemic Therapy | recruiting | N/A | 534 | Fudan UniversityOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07835698 | The Validation of ICBT Clinical Trial: Disease Stress Adjustment in Breast Cancer Patients(ICBT-TW-2) | not yet recruiting | N/A | 100 | National Health Research Institutes, TaiwanOTHER | 0 | Sep 23, 2026 | clinicaltrials |
| NCT07836257 | A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXd | not yet recruiting | Phase 2 | 28 | Fujian Medical UniversityOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT01174121 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | recruiting | Phase 2 | 332 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02484404 | Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... | active not recruiting | Phase 1 / Phase 2 | 268 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03766009 | Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making | active not recruiting | N/A | 627 | Alliance for Clinical Trials in OncologyOTHER | 3 | Sep 22, 2026 | clinicaltrials |
| NCT04994067 | Intra-Operative Radiation Registry | recruiting | — | 460 | Albert Einstein College of MedicineOTHER | 1 | Sep 22, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials